
Aptose Biosciences APTO
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
2.45 M |
Market Cap[1] |
$ 1.2 M |
EBITDA (LTM) |
$ 22 K |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
-10.41 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
BioLineRx Ltd.
BLRX
|
$ 2.32 | 2.67 % | $ 5.72 B | Nasdaq Capital Market | ||
|
BioMarin Pharmaceutical
BMRN
|
$ 60.0 | 0.22 % | $ 11.5 B | Nasdaq Global Select Market,SPB | ||
|
Bristol-Myers Squibb Company
BMY
|
$ 62.4 | 0.19 % | $ 127 B | NYSE,SPB | ||
|
Benitec Biopharma
BNTC
|
$ 10.0 | 2.56 % | $ 466 M | Nasdaq Capital Market | ||
|
BioNTech SE
BNTX
|
$ 98.3 | 0.02 % | $ 23.8 B | Nasdaq Global Select Market | ||
|
Burford Capital Limited
BUR
|
$ 3.92 | 0.51 % | $ 859 M | NYSE | ||
|
BeyondSpring
BYSI
|
$ 0.77 | 2.15 % | $ 31.7 M | Nasdaq Capital Market | ||
|
Cabaletta Bio
CABA
|
$ 1.92 | 0.75 % | $ 193 M | Nasdaq Global Select Market | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 2.2 | 0.92 % | $ 3.62 M | NYSE American | ||
|
Capricor Therapeutics
CAPR
|
$ 9.47 | 10.5 % | $ 440 M | Nasdaq Capital Market | ||
|
Catalyst Biosciences
CBIO
|
$ 14.59 | 1.58 % | $ 1.3 B | Nasdaq Capital Market | ||
|
C4 Therapeutics
CCCC
|
$ 3.33 | 6.39 % | $ 276 M | Nasdaq Global Select Market | ||
|
Codexis
CDXS
|
$ 1.39 | 2.96 % | $ 121 M | Nasdaq Global Select Market | ||
|
Cerus Corporation
CERS
|
$ 2.38 | 0.82 % | $ 454 M | Nasdaq Global Market | ||
|
Certara
CERT
|
$ 9.2 | 0.11 % | $ 1.48 B | Nasdaq Global Select Market | ||
|
Cullinan Management
CGEM
|
$ 15.35 | 0.79 % | $ 925 M | Nasdaq Global Select Market | ||
|
Compugen Ltd.
CGEN
|
$ 2.38 | 1.28 % | $ 222 M | Nasdaq Global Market,SPB | ||
|
Coherus BioSciences
CHRS
|
$ 1.21 | 2.54 % | $ 142 M | Nasdaq Global Market | ||
|
Celldex Therapeutics
CLDX
|
$ 32.41 | 2.43 % | $ 2.15 B | Nasdaq Global Select Market | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
$ 3.78 | 0.13 % | $ 46.1 M | Nasdaq Capital Market | ||
|
Cellectis S.A.
CLLS
|
$ 1.51 | 2.72 % | $ 151 M | Nasdaq Global Market | ||
|
Cellectar Biosciences
CLRB
|
$ 1.84 | 1.1 % | $ 4.8 M | Nasdaq Capital Market | ||
|
CNS Pharmaceuticals
CNSP
|
$ 5.3 | 8.0 % | $ 2.35 M | Nasdaq Capital Market | ||
|
Cocrystal Pharma
COCP
|
$ 1.15 | 2.68 % | $ 13 M | Nasdaq Capital Market | ||
|
Collegium Pharmaceutical
COLL
|
$ 21.82 | 0.44 % | $ 691 M | Nasdaq Global Select Market | ||
|
Corcept Therapeutics Incorporated
CORT
|
$ 115.23 | 0.43 % | $ 12 B | Nasdaq Capital Market,SPB | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
$ 6.82 | 2.87 % | $ 90.8 M | Nasdaq Global Market | ||
|
Cardiff Oncology
CRDF
|
$ 1.21 | 3.42 % | $ 80.9 M | Nasdaq Capital Market | ||
|
Curis
CRIS
|
$ 0.84 | 1.21 % | $ 11.1 M | Nasdaq Global Market | ||
|
CorMedix
CRMD
|
$ 7.7 | 0.51 % | $ 555 K | Nasdaq Global Market | ||
|
CRISPR Therapeutics AG
CRSP
|
$ 55.32 | 0.02 % | $ 4.97 B | Nasdaq Global Market,SPB | ||
|
Corvus Pharmaceuticals
CRVS
|
$ 11.52 | 0.85 % | $ 910 M | Nasdaq Global Market | ||
|
Champions Oncology
CSBR
|
$ 5.0 | 4.38 % | $ 69.2 M | Nasdaq Capital Market | ||
|
CytomX Therapeutics
CTMX
|
$ 2.72 | 2.23 % | $ 375 M | Nasdaq Global Select Market | ||
|
Citius Pharmaceuticals
CTXR
|
$ 0.53 | 0.41 % | $ 5.86 M | Nasdaq Capital Market | ||
|
Cue Biopharma
CUE
|
$ 25.87 | 1.41 % | $ 2.45 B | Nasdaq Capital Market,SPB | ||
|
CEL-SCI Corporation
CVM
|
$ 2.06 | 15.73 % | $ 16.5 M | NYSE American,SPB | ||
|
Cytokinetics, Incorporated
CYTK
|
$ 65.91 | 0.41 % | $ 7.92 M | Nasdaq Global Select Market,SPB | ||
|
Daré Bioscience
DARE
|
$ 0.85 | 4.7 % | $ 9.5 M | Nasdaq Capital Market | ||
|
DBV Technologies S.A.
DBVT
|
$ 11.76 | 1.82 % | $ 1.64 B | Nasdaq Global Select Market | ||
|
DiaMedica Therapeutics
DMAC
|
$ 8.27 | 0.85 % | $ 389 M | Nasdaq Capital Market | ||
|
Denali Therapeutics
DNLI
|
$ 20.67 | 0.38 % | $ 3.57 B | Nasdaq Global Select Market,SPB | ||
|
Precision BioSciences
DTIL
|
$ 6.26 | 1.29 % | $ 80.3 M | Nasdaq Global Select Market | ||
|
Dyadic International
DYAI
|
$ 0.44 | 0.49 % | $ 15.9 M | Nasdaq Capital Market | ||
|
Editas Medicine
EDIT
|
$ 2.57 | 0.19 % | $ 228 M | Nasdaq Global Select Market,SPB | ||
|
Edesa Biotech
EDSA
|
$ 4.21 | 18.26 % | $ 23.9 M | Nasdaq Capital Market | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 0.5 | 4.73 % | $ 22.8 M | Nasdaq Capital Market | ||
|
Enanta Pharmaceuticals
ENTA
|
$ 13.18 | 4.27 % | $ 281 K | Nasdaq Global Select Market,SPB | ||
|
Entera Bio Ltd.
ENTX
|
$ 2.91 | 8.18 % | $ 134 M | Nasdaq Capital Market | ||
|
Equillium
EQ
|
$ 1.63 | 0.31 % | $ 93.4 M | Nasdaq Global Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.